The European Union plans to phase out components and equipment from high-risk suppliers in critical sectors, according to a ...

Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for ...

Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The ...

Trump launches phase two of Gaza plan focusing on demilitarization Hamas and reconstruction, but experts warn disarming Hamas ...

At the same time developed markets have been generating policy and macro noise, emerging markets have been quietly ...

We’re still waiting to find out whether President Donald Trump follows through and strikes Iran after the country violated ...

As 2026 unfolds, investors are seeking top crypto to buy opportunities that balance stability with high growth potential ...

As the next bull run approaches, investors are focusing on building a portfolio that balances established networks wit ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Delhi may need to scale up its Metro network to more than twice its current operational length to effectively curb vehicular ...

Rajiv Sabharwal, MD & CEO of Tata Capital, said the company has seen strong growth in disbursements in the October-December ...